Navigation Links
Transplant Head Honcho forced to dismount

The Abdominal Transplant Program, beset with administrative problems, experienced another upheaval. In a recent statement, The UCSD communicated its decision to relieve // Dr. Hart, the Director of the program for liver and kidney transplants, of his administrative responsibilities. Notwithstanding, Dr Hart will still continue as a full-time surgeon and member of the University's transplant team.

The UC San Diego, disappointed with the manner in which Dr Marquis Hart had conducted the UC Irvine’s Liver program, perceived to have misled organ officials, instigated his exit. Dr Marquis Hart had been offering part time services to the UCI since 2002 till the fall of 2005. During his tenure, The UCI liver program suffered huge setbacks prompting its closure.

Federal officials said that though the UCI was given 122 livers between 2004 and 2005, only 12 transplantations had occurred, a record low for any such program in the state. The UCI also did not have its own team of surgeons and therefore had to avail the services of Marquis and another UCSD surgeon. Further, Medicare also decided to cancel the payment for UCI’s Liver transplants.

Dr Hart was also part of a contract that allowed him to be a consultant surgeon for the UCI. The financial contract, according to Dr Thomas MacAfee, was between the UC Irvine and The UCSD Department of Surgery, and confirmed that the UCSD was not in the eye of any mischief or allegations. In the UCSD statement, the Chief Executive Officer, Richard Liekweg has reiterated that this is not a slur on the Doctor’s skill and commitment to his work. Infact, Dr Hart is regarded as an outstanding surgeon, deeply committed to his patients.

'"/>




Page: 1

Related medicine news :

1. Stem Cell Transplants May Be Effective For MS Patients
2. Drugs Deter Heart Disease for Transplant Patients
3. Better Drug for Heart Transplant
4. Kidney Failure after Non-Kidney Transplants
5. Measles Risk in Transplant Patients
6. Transplants Help Liver Cancer Patients
7. Steroid-Free Liver Transplants
8. Pancreas Transplant for Diabetics
9. Reducing The Risk Of Fractures After a Heart Transplant
10. A Urine Test Could Predict Rejection In Transplant Patients
11. Thawed Ovarian Transplant
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... June 28, 2017 , ... The parent company ... in employee engagement. Omaha-based C&A Industries, a national leader in staffing and ... in North America for 2017. The annual award, issued by Achievers, ...
(Date:6/28/2017)... ... June 28, 2017 , ... Anyone with a remote control has seen the never-ending twists on ... the flipper will get rich in no time. But what about the buyers of ... for the buyer of a flipped house. An email recently sent to Gary Case ...
(Date:6/28/2017)... ... 2017 , ... Park Systems , a leader in Atomic Force Microscopy ... attendees and Park customers on July 11, 2017 from 12-2pm at the Thirsty Bear ... CEO of Park Systems, and Prof. Krishna Saraswat , Rickey/Nielsen Professor in the ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, the ... the health care industry’s hospitals and provider groups, has announced that it will ... customers. Parasail Health is a San Francisco health-finance startup that has launched a ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences ... Company specializing in the development of cannabinoid-based drugs, ... a company overview at three upcoming scientific and ... Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: